Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Other notable mutations identified in ICP patients include ones in the farnesoid X receptor (FXR), a nuclear receptor in hepatocytes which activates transcription of MDR3 and BSEP upon binding intracellular bile acids, thereby increasing canalicular bile efflux.
== See also == S&P 1500 – US broad stock market index from S&P Dow Jones Indices Russell 2500 Index Russell 2000 Index – U.S. small-cap stock market index Russell 1000 Index – U.S. large-cap stock market index Wilshire 5000 – US total stock market index
Some have pores underneath, others have spines, such as the hedgehog mushroom and other tooth fungi, and so on. "Mushroom" has been used for polypores, puffballs, jelly fungi, coral fungi, bracket fungi, stinkhorns, and cup fungi. Thus, the term is more one of common application to macroscopic fungal fruiting bodies than one having precise taxonomic meaning. Approximately 14,000 species of mushrooms are described.
== Sources == Flegel, Melinda J. (2004). Sport first aid: A coach's guide to preventing and responding to injuries. Hong Kong, Japan: Human Kinetics. Lindsay, R., Watson, G., Hickmont, D., Broadfoot, A., & Bruynel, L. (1994). Treat your own strains sprains and bruises. New Zealand: Spinal Publications. Lovering, R.M. (2008). "Physical therapy and related interventions". In P.M. Tiidus (ed.), Skeletal muscle damage and repair (pp. 219–230). United States of America: Human Kinetics. Prentice, William E. "Tissue Response to Injury", Principles of Athletic Training: A Competency Based Approach. 14th ed. New York: McGraw Hill Companies, 2011. 260–277. Subotnick, Steven (1991). Sports and Exercise Injuries: Conventional, Homeopathic and Alternative Treatments. California, United States of America: North Atlantic Books.
Factors include reputation, nature or behaviour of customers, complex ownership, customer domicile, presence of nominee shareholders, cash-intensive businesses, use of new technologies or transactions linked to oil, tobacco, arms, precious metals or stones. Bank employees, such as tellers and customer account representatives, are trained in anti–money laundering and are instructed to report activities that they deem suspicious. Sectors subject to AML/CFT legislation are legally required to maintain internal processes capable of monitoring customers and transactions, meeting CDD and EDD obligations and identifying and reporting suspicious activities to relevant regulators and law enforcement. Financia institutions that fail to comply with these requirements face threats to their reputation and heavy fines, sometimes running into billions of dollars. Additionally, anti–money laundering software filters customer data, classifies it according to level of suspicion, and inspects it for anomalies. Such anomalies include any sudden and substantial increase in funds, a large withdrawal, or moving money to a bank secrecy jurisdiction. Smaller transactions that meet certain criteria may also be flagged as suspicious. For example, structuring can lead to flagged transactions. The software also flags names on government "blacklists" and transactions that involve countries hostile to the host nation. Once the software has mined data and flagged suspect transactions, it alerts bank management, who must then determine whether to file a report with the government.
Sources: en.wikipedia.org
== History == Hemoglobin was discovered as some sort of crystal formed from earthworm body fluid and animal blood by German biochemist Friedrich Ludwig Hünefeld at Leipzig University in 1840. When the protein nature was established another German Felix Hoppe-Seyler gave the name hemoglobin (literally "blood protein") in 1864. Its role as an oxygen transporter was later established. While studying sickle cell disease, Linus Pauling and Harvey Itano at the California Institute of Technology discovered in 1949 that the disease was due to abnormal hemoglobin, later called hemoglobin S (HbS). In 1950, Itano and James V. Neel discovered a slightly different case in which individuals had sickled red blood cells but not anemia. The hemoglobin was named hemoglobin III, but later known as hemoglobin C (HbC).
Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta and Kaftrio, is a fixed-dose combination medication used to treat cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators. The combination is approved for medical use in the United States for people aged two years of age and older who have cystic fibrosis with a F508del mutation or other mutations in the CFTR gene. It is also approved for use in Canada, the European Union, and Australia. The combination is on the World Health Organization's List of Essential Medicines.
An insurgent was killed and eight captured in a military operation in the Greda Shah Jahan village of Bannu District, while three more alleged militants were captured from Saidu Sharif by police. Two children were injured in an insurgent mortar attack Dabar Malano Jalwaana area of Wara Mamund tehsil. On 20 July, four militants were killed in a military operation in Lakrai area of Mohmand District while six were killed in raids throughout Bannu District, six IEDs were also neutralized in Bannu District. Three Excise Department personnel were abducted from a checkpoint on the Dalbandin–Taftan Highway in Chagai District. On 21 July, a peace committee member was assassinated by an IED attack in Karrapa area of Hangu District while TTP claimed to have killed two in the Muhammad Khel area of Boya Tehsil. The Wadigram area in Salarzai Tehsil was hit by two mortar shells while insurgents blew up a Government school in Mamund Tehsil. On 22 July, a TTP insurgent was captured from the Syed Ali Mela Khor area of Kurram District while three were captured from Khyber District, three more were killed in a military operation in Chapri Naryab Chowk area of Hangu District. On 23 July, insurgents ambushed and killed a Police Constable near Moula Khan Sarai in the Sarwekai area of South Waziristan District. Four TTP militants were killed and five captured in a military operation in Talgai mountains of Wazir Tehsil, while two militant hideouts were destroyed in the Sipah Tandi Kalay area of Bara.
While in Constantine's treatise Liber de Coitu, the clitoris is referred to a few times, Magnus gave an equal amount of attention to male and female organs. Like Avicenna, Magnus also used the word virga for the clitoris, but employed it for the male and female genitals; despite his efforts to give equal ground to the clitoris, the cycle of suppression and rediscovery of the organ continued, and a 16th-century justification for clitoridectomy appears to have been confused with intersex conditions and the imprecision created by the word nymphae substituted for the word clitoris. Nymphotomy was a medical operation to excise an unusually large clitoris, but what was considered "unusually large" was often a matter of perception. The procedure was routinely performed on Egyptian women, due to physicians such as Jacques Daléchamps who believed that this version of the clitoris was "an unusual feature that occurred in almost all Egyptian women [and] some of ours, so that when they find themselves in the company of other women, or their clothes rub them while they walk or their husbands wish to approach them, it erects like a male penis and indeed they use it to play with other women, as their husbands would do ... Thus the parts are cut".
Emissions from vehicles such as cars and trucks can be a substantial outdoor source of PAHs in particulate air pollution. Geographically, major roadways are thus sources of PAHs, which may distribute in the atmosphere or deposit nearby. Catalytic converters are estimated to reduce PAH emissions from gasoline-fired vehicles by 25-fold. People can also be occupationally exposed from using fossil fuels or their derivatives, wood-burning, carbon electrodes, or exposure to diesel exhaust. Industrial activity that can produce and distribute PAHs includes aluminum, iron, and steel manufacturing; coal gasification, tar distillation, shale oil extraction; production of coke, creosote, carbon black, and calcium carbide; road paving and asphalt manufacturing; rubber tire production; manufacturing or use of metal working fluids; and activity of coal or natural gas power stations. In industrial countries, people who smoke tobacco products, or who are exposed to second-hand smoke, are among the most highly exposed groups; tobacco smoke contributes to 90% of indoor PAH levels in the homes of smokers. For the general population in developed countries, the diet is otherwise the dominant source of PAH exposure, particularly from smoking or grilling meat or consuming PAHs deposited on plant foods, especially broad-leafed vegetables, during growth. Exposure also occurs through drinking alcohol aged in charred barrels, flavored with peat smoke, or made with roasted grains. PAHs are typically at low concentrations in drinking water.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.